Development of a scalable process for DG-041, a potent EP3 receptor antagonist, via tandem heck reactions

…, V Rajagopol, W Zeller, M O'Connell…

文献索引：Zegar, Siead; Tokar, Christopher; Enache, Livia A.; Rajagopol, Venkat; Zeller, Wayne; O'Connell, Matthew; Singh, Jasbir; Muellner, Frank W.; Zembower, David E. Organic Process Research and Development, 2007 , vol. 11, # 4 p. 747 - 753

全文：HTML全文

被引用次数: 31

摘要

DG-041 is a small molecule antagonist of the EP3 receptor for prostaglandin E2 that is in clinical development for treatment of peripheral artery disease (PAD). Originally produced using a six-step synthetic procedure, process optimization led to development of a four-step sequence that is readily scalable. The key step in the optimized sequence contains two sequential Heck reactions, involving an intramolecular Heck cyclization followed by an ...